Drug Database
ZO

zolpidem tartrate (Intermezzo / zolpidem, TransOral)

✓ Approved

Transcept Pharmaceuticals · GABRA1 · 小分子

什么是 zolpidem tartrate?

zolpidem tartrate 是一种小分子,由Transcept Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)、Sublingual (SL)/Oral Transmucosal。

药物档案

商品名Intermezzo, zolpidem, TransOral
公司Transcept Pharmaceuticals
药物类别小分子
分子靶点GABRA1
给药途径Oral (PO), Sublingual (SL)/Oral Transmucosal
状态Approved

作用机制

分子靶点

zolpidem tartrate 作用于 1 个分子靶点:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

zolpidem tartrate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersInsomnia✓ Approved

相关研究文献

PubMedBone research2026-09-10

WDR23 prevents bone loss by promoting autophagic degradation of TRAF6 in osteoclastogenesis.

Park Hye-Won HW, Yu Jungeun J, Yu Jiyeon J, You Jinseon J et al.

Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a pivotal adaptor molecule in the receptor activator of nuclear factor-κB (RANK) and its ligand (RANKL) signaling pathways, which are essential for osteoclastogenesis. In this study, we identified WD40 repeat-containing protein 23 (WDR23), also known as DDB1-CUL4 associated factor 11 (DCAF11), as a novel binding partner of TRAF6. Our findings demonstrate that WDR23/DCAF11 acts as a negative feedback regulator of RANK/RANKL-induced osteoclastogenesis by promoting the autophagy-dependent degradation of TRAF6. Notably, RANKL induced the upregulation of WDR23 expression during osteoclastogenesis. WDR23 physically interacted with the TRAF domain of TRAF6 via the WD40 repeat domains 1 and 2 of WDR23, resulting in reduced TRAF6 protein stability by its autophagy-dependent degradation during osteoclastogenesis. By modulating TRAF6 protein levels, WDR23 attenuated RANKL signaling cascades, including nuclear factor-κB and mitogen-activated protein kinases, thereby downregulating the expression of osteoclastogenic markers, such as nuclear factor of activated T-cell c1, tartrate-resistant acid phosphatase, dendritic cell-specific transmembrane protein, V-ATPase subunit d2 and cathepsin K. Conversely, WDR23 knockdown or deficiency enhanced RANKL-induced osteoclastogenesis by preventing the autophagy-dependent degradation of TRAF6. WDR23-deficient mice exhibit an osteoporotic bone phenotype characterized by elevated osteoclast formation and reduced bone mass. Collectively, these results establish WDR23 as a key negative feedback regulator of RANKL-induced osteoclastogenesis via autophagy-mediated TRAF6 degradation and underscore its potential as a therapeutic target for bone disorders associated with aberrant osteoclast formation and function.

PMID 42717193
阅读全文 →
PubMedBiomedical chromatography : BMC2026-09-09

LC-MS/MS Method for Simultaneous Quantification of Zolpidem, Zopiclone, and Their Metabolites in Human Urine and Its Pharmacokinetic Application.

Chauhan Varsha V, Sharma Manu M, Taha Murtada M, Kumar Manish M et al.

Zolpidem (Z1) and zopiclone (Z2) are widely prescribed for insomnia; but their misuse in drug-facilitated crimes presents significant forensic and clinical challenges. This study aimed to develop and validate a simple and sensitive LC-MS/MS method, coupled with dispersive liquid-liquid microextraction (DLLME), for the simultaneous determination of Z1, Z2, and 18 phase I and phase II metabolites (20 species) in human urine. DLLME employed 1 mL of dichloromethane as extractant and 2 mL of acetonitrile as disperser per 2 mL of urine, reducing halogenated-solvent use compared with conventional liquid-liquid extraction. Chromatographic separation was achieved on a HyPURITY C18 column with water-acetonitrile (70:30, v/v) containing 0.2% formic acid. Z1 and Z2 were validated according to ICH guidelines over 0.1-200 ng/mL, showing linearity (R2 > 0.999), accuracy (96.29%-99.56%), precision (RSD ≤ 3.12%), and recovery (96.12%-98.74%). Because authentic metabolite standards were unavailable, metabolite concentrations were estimated using parent-drug calibration curves and are considered semi-quantitative. In five healthy volunteers, hydroxylated and carboxylated metabolites peaked at 2-12 h and remained detectable up to 84 h. These findings support the method's potential for retrospective urinary screening of Z-drug exposure in forensic and clinical toxicology.

PMID 42714029
阅读全文 →
PubMedPediatrics2026-09-07

A 6-Year-Old With Becker Muscular Dystrophy and Catatonia.

Lichtor Stephanie A SA, Robinson Mars M, Luccarelli James J, Pumphrey Katherine K et al.

Catatonia is often underrecognized and underdiagnosed, particularly in young children. Catatonia occurs secondary to a medical and/or psychiatric etiology. The diagnosis can be supported by validated rating scales, including the Pediatric Catatonia Rating Scale and/or response to a dose of a benzodiazepine, often lorazepam. We present the case of a 6-year-old boy with acute behavioral changes in speech, affect, awareness, and new odd behaviors, admitted to a quaternary care pediatric hospital for further assessment and work-up of symptoms consistent with catatonia. Laboratory testing was notable for previously undiagnosed Becker muscular dystrophy (BMD), although otherwise unremarkable. He received many medication treatments for catatonia, including escalating doses of lorazepam and augmentation with memantine, zolpidem, quetiapine, and ultimately clozapine, without adequate symptom improvement and with side effects including significant weight gain. Neither behavioral interventions nor empirical treatment of presumed seronegative autoimmune encephalitis with intravenous immunoglobulin and methylprednisolone conferred benefit. He ultimately received electroconvulsive therapy, with significant and relatively rapid improvement occurring over 2 weeks after a 4-month hospitalization. This case highlights the importance of the identification of catatonia to guide evidence-based treatment and the value of timely access to electroconvulsive therapy for pediatric patients. While the etiology of his catatonia remains undetermined, his diagnosis of BMD could play a role and further supports the importance of a comprehensive medical work-up.

PMID 42705646
阅读全文 →
PubMedAnimal nutrition (Zhongguo xu mu shou yi xue hui)2026-09-06

Chondroitin sulfate modulates gut microbiota to improve bone metabolism and reduce locomotion problems in yellow-feathered broilers.

Xue Yuyang Y, Yao Min M, Peng Xiangjian X, Wang Fang F et al.

Chondroitin sulfate (CS) is known to promote bone health, but its effects on skeletal development and gut microbiota in yellow-feathered broilers remain largely unexplored. This study aimed to evaluate the effects of CS on bone health, growth performance, and intestinal flora in broilers. A total of 720 one-d-old Jinling yellow-feathered broilers (initial body weight 37.0 ± 0.5 g) were randomly divided into four treatment groups, each with nine replicates of 20 birds. The control group was fed a basal diet (CON), while the experimental group was supplemented with low (LCS), medium (MCS), or high CS (HCS) levels (0.05%, 0.15%, or 0.30%) for 30 d. Samples were collected every 10 d during a supplementation period of 30 d and again at 63 d to investigate the effect of early supplementation of CS on bone development later in life. Chondroitin sulfate supplementation improved broiler growth performance only at the beginning of the study. Compared with the CON group, the MCS group significantly increased tibial weight and length, and improved mid-segment geometric parameters, including vertical wall thickness (WTv), cross-sectional moment of inertia (CSMI), and cross-sectional area (CSA) (P < 0.05). The MCS group optimized bone trabecular structure, increased bone volume/tissue volume (BV/TV) and trabeculae thickness (Tb.Th) (P < 0.05); promoted new bone formation, and enhanced bone Ca and P deposition, compared with the CON. Chondroitin sulphate supplementation significantly decreased serum bone resorption markers tartrate resistant acid phosphatase (TRAP), elevated bone formation markers bone specific alkaline phosphatase (BALP) at 30 d, and down-regulated the expression levels of bone resorption-related genes (TRAP and RANKL) (P < 0.05). Compared with the CON group, the MCS group significantly increased the abundance of p_Bacillota_A_368345, Faecalibacterium, and Brotaphodocola (P < 0.05); and decreased the abundance of harmful bacterial genera. Functional prediction showed that the MCS group down-regulated some pro-inflammatory and tricarboxylic acid (TCA) cycle-related pathways and up-regulated carbohydrate degradation pathways (P < 0.05), compared with the CON group. In conclusion, CS supplementation improved bone quality, and altered the composition of intestinal flora during broiler growth.

PMID 42701456
阅读全文 →
PubMedJournal of magnetic resonance imaging : JMRI2026-09-05

Editorial for "Sublingual Zolpidem for MRI in Claustrophobic Patients: A Prospective, Non-Randomized Noninferiority Study".

Haider Zain Z, McInnes Matthew Df MD, Harper Kelly K

PMID 42698147
阅读全文 →
PubMedDrug research2026-09-03

Nortrachelogenin Inhibits Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Nuclear Factor Kappa-B Signaling and Osteoclastogenesis.

Zhang Lifang L, Basit Farwa F, Kumar Santosh S, Deepak Vishwa V

Nortrachelogenin is a dibenzylbutyrolactone lignan associated with redox-sensitive signaling. We examined its effects on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced nuclear factor kappa-B (NF-κB) activation in osteoclast precursors. Nortrachelogenin attenuated IκB phosphorylation and degradation and reduced p65 phosphorylation. Consistently, it markedly decreased the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts. These findings identify nortrachelogenin as a lignan scaffold that suppresses nuclear factor kappa-B signaling and osteoclastogenesis in vitro.

PMID 42692070
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多zolpidem tartrate